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Abstract
Aim: Late-onset Alzheimer’s disease (LOAD) accounts for 95% of all Alzheimer’s cases and is
genetically complex in nature. Overlapping clinical and neuropathological features between AD, FTD
and Parkinson’s disease highlight the potential role of genetic pleiotropy across diseases. Recent
GWAS have uncovered 20 new loci for AD risk, however these exhibit small effect sizes. Using NGS,
here we perform association analyses using exome-wide and candidate-gene driven approaches.
Methods: Whole-exome sequencing was performed on 132 AD cases and 53 control samples. Exome-
wide single variant association and gene burden tests were performed for 76,640 non-singleton variants.
Samples were also screened for known causative mutations in familial genes in AD and other
dementias. Single variant association and burden analysis was also carried out on variants in known
AD and other neurologic dementia genes.
Results: Tentative single variant and burden associations were seen in several genes with kinase and
protease activity. Exome-wide burden analysis also revealed significant burden of variants in PILRA
(P=3.4x10-5), which has previously been linked to AD via GWAS, hit ZCWPW1. Screening for causative
mutations in familial AD and other dementia genes revealed no pathogenic variants. Variants identified
in ABCA7, SLC24A4, CD33 and LRRK2 were nominally associated with disease (P<0.05) but did not
withstand correction for multiple testing. APOE (P=0.02) and CLU (P=0.04) variants showed significant
burden on AD.
Conclusions: In addition, polygenic risk scores (PRS) were able to distinguish between cases and
controls with 83.8% accuracy using 3,268 variants, sex, age at death and APOE ε4 and ε2 status as 
predictors.
Abbreviations
AD – Alzheimer’s disease
AUC – area under curve
BDR – Brains for Dementia Research
DLB – Dementia with Lewy bodies
fEOAD – familial early onset Alzheimer’s disease
FTD – Frontotemporal dementia
GWAS – genome-wide association study
LOAD – late onset Alzheimer’s disease
MAF – minor allele frequency
NGS – next generation sequencing
OR – odds ratio
P – P-value
PCR – polymerase chain reaction
PD – Parkinson’s disease
PRS – polygenic risk score
1. Introduction
Alzheimer's disease (AD) is the most common form of dementia, affecting over 850,000 people in the
UK alone, a number expected to rise to 1 million by 2025 [1]. There are two forms distinguished by the
age when symptoms first appear. In the early-onset familial form (fEOAD), symptoms appear before
65 years of age, however this only accounts for about 5% of cases [2]. Mutations in the familial genes
APP, PSEN1 and PSEN2 are rare but highly penetrant. Individuals with these mutations are almost
certain to develop fEOAD [3]. The majority of cases are sporadic in nature and classified as late-onset
(LOAD), with symptoms appearing at 65 years or later. This represents the other 95% of all incidences
[4]. Presence of the APOE ε4 allele is the largest known genetic risk factor for LOAD, with a 2-3 fold 
increase in risk for carriers and 15 fold for individuals homozygous for the ε4 allele [5]. The rare ε2 
allele confers a protective effect and appears to reduce AD risk by up to 40%.
Genome-wide association studies (GWAS) have identified 20 risk variants associated with LOAD [6–
9]; this has implicated several new pathways in AD, such as endocytic processing, inflammation and
cholesterol transport [8]. Although highly replicable in Caucasian groups, these effects have been
difficult to replicate in other populations [10]. These common variants also exert only small effects on
disease risk, which does not account for much of the missing heritability in AD. It is likely that low
frequency variants, not detected by GWAS, could have greater effect sizes and therefore explain more
of the heritable component.
Advances in next-generation sequencing (NGS) in recent years have allowed exomes and entire
genomes to be explored at single-base level. The exome accounts for approximately 1% of the human
genome, yet it harbours almost 85% of known mutations underlying disease-related traits [11].
Therefore, rare mutations can be identified using this technology. Whole-exome sequencing (WES)
has identified a rare variant in the TREM2 gene, R47H, associated with a 5-fold increase in AD risk
[12]. These studies have also found rare causative variants in CLU and SORL1 that were overlooked
by GWAS [13]. By identifying the genetic variants of individuals, WES has the potential to uncover
more rare variants associated with AD risk.
There are several overlapping clinical and neuropathological features across different dementias. For
example, dementia with Lewy bodies (DLB) shares clinical features with AD and Parkinson’s disease
(PD), often resulting in misdiagnosis. PD and DLB are both synucleinopathies presenting with alpha-
synuclein deposits in the brain, whereas APOE ε4 increases risk of disease in AD and DLB [14]. This 
suggests that genetic risk factors may contribute to more than one disease, known as genetic
pleiotropy, whereby a gene or DNA variant can influence multiple phenotypes.
Clinically well-characterised brain tissue samples from healthy individuals remains a limiting factor in
the study of neurological disorders [15], Brains for Dementia Research (BDR)
(www.brainsfordementiaresearch.org.uk) is a network of six leading UK brain banks (jointly funded by
Alzheimer’s Research UK and Alzheimer’s Society), specifically created to address the shortages of
high-quality brain tissue samples from healthy individuals as well as those with dementia. This project
is a planned brain donation programme with over 3000 participants, aged 65 years and above, with
and without the diagnosis of dementia. Regular, standardised cognitive and psychiatric assessment of
potential brain donors during life is critical in optimising the value of brain tissue for research [16,17].
We performed single variant and burden analysis on coding variants to identify significant associations
with LOAD. We also report on screening of 132 LOAD patients from the Brains for Dementia Research
(BDR) resource with the aim to identify causative or predicted pathogenic coding variants in 40
selected genes. Of these, 16 are associated with familial forms of neurodegeneration, including
fEOAD (APP, PSEN1 and PSEN2), frontotemporal dementia (FTD) and Amyotrophic lateral sclerosis
(ALS) (C9or72, CHMP2B, FUS, GRN, MAPT, TARDBP and VCP), PD (LRRK2, PARK2, PARK7,
PINK1 and SNCA) and Prion disease (PRNP). The remaining genes were selected from AD GWAS
and NGS (20 GWAS, APOE and TREM2).
Polygenic risk scores (PRS) have been increasingly used to investigate the effect of multiple genetic
variants on disease traits. It is based on the notion that many variants with small effects will not be
detectable at genome-wide significance, however collectively they may have a strong effect [18]. PRS
were generated to examine the association between multiple genetic markers and their collective
effects on LOAD.
2. Materials and Methods
2.1 BDR samples
The BDR cohort comprised of 132 clinically diagnosed LOAD (age at onset >65 years) cases and 53
cognitively normal controls; all diagnoses were neuropathologically confirmed (Supplementary Table
S1). Neuropathological diagnoses were undertaken by experienced neuropathologists within the
Brains for Dementia Research network and were based on Thal Aβ phases [19],  neurofibrillary tangle 
Braak stages [20], Consortium to Establish a Registry for Alzheimer’s disease (CERAD) criteria for AD
[21] which are all combined in the National Institute on Aging – Alzheimer’s Association guidelines
[22], together with the Newcastle / McKeith criteria for Lewy body disease [23] and for FTLD-TDP as
described by [24]. Whilst there are no fully established criteria for vascular pathology the VCING
criteria were used [25] along with those proposed by Smallwood et al (2012) [26] and Grinberg and
Thal (2010) [27].
Demographics of case and control samples for each centre are shown in Table 1. The average age at
death was 82.5 years (range 65-101 years) for LOAD samples. For control individuals, average age at
death was 85.9 years (range 58-104 years). The proportion of females between cases and controls
were similar, accounting for around 50% of the total sample size. APOE ε4 carriers were 3-fold higher 
in cases (64.7%) with almost one fifth (17.3%) being homozygous for the ε4 allele. In comparison only 
24.5% of controls were carriers and no individuals were ε4ε4. The ε2 allele was present in 10 control 
samples (18.9%) and 8 cases (6.2%), with both a case and control sample being homozygous for the
allele. The higher 3-fold frequency observed in control samples correlates with the protective effect of
the ε2 allele. All samples in the BDR cohort used for analysis were classified as AD or control by 
neuropathology.
The BDR has a number of neuropathological features available for more definitive analysis of
genotype-phenotype correlation [28]. Data includes the CERAD scale, Braak tangle and Lewy body
staging, with simplified measures (present/absent; mild/moderate/severe) of small vessel disease,
deposition of TDP-43 protein, arteriolar Aβ-CAA and cerebrovascular atherosclerosis. Detailed clinical 
and cognitive information on the samples is also available upon request, demonstrating the potential
value of the BDR cohort for very detailed analyses in future studies as more extensive genetic data is
generated.
2.2 DNA extraction
DNA was extracted from brain tissue using standard phenol-chloroform procedures. Samples were
analysed on the Agilent TapeStation and quantified using the Nanodrop 3300 spectrometer to ensure
high concentration and quality material was obtained. Samples were genotyped for APOE ε2, ε3 and 
ε4 alleles using the TaqMan method (Applied Biosystems) to determine APOE status.
2.3 Exome sequencing library prep
DNA libraries were hybridised to exome-capture probes with Agilent SureSelect Human All Exon Kit
V4 for Illumina GA (Agilent Technologies) as per manufacturer’s protocol. Exome-enriched libraries
were sequenced on the Illumina HiSeq 2500 using 2 x 100bp paired end read cycles. The Agilent
capture library includes 5’ and 3’ untranslated regions.
2.4 Bioinformatics
Paired-end sequence reads were aligned to the human reference genome build 19 (UCSC hg19)
using Burrows-Wheeler Aligner [29]. Format conversion, indexing and removal of PCR duplicates
were performed with Picard (www.picard.sourceforge.net/index.shtml). The Genome Analysis Toolkit
was used for recalibration of base quality scores, realignment around indels and variant calling [30].
Variants were annotated using ANNOVAR [31] and Variant Effect Predictor [32] predicted SIFT and
Polyphen2 scores of protein coding variants. Consistency between SIFT and Polyphen2 predictions
and the databases allowed more reliable classification. Variants were also checked against
established databases (dbSNP v.149, 1000 Genomes Project and Exome Variant Server).
2.5 Filtering
Singleton variants with MAF < 0.002 were removed in VCFtools [33]. Coding variants in genes were
filtered by annotation with SnpSift [34]. Visualisation of variants was performed, when necessary,
using Integrative Genomics Viewer [35]. Individuals with a calculated age at onset below 65 years
were removed and samples were screened for causative mutations in fEOAD genes APP, PSEN1 and
PSEN2 to ensure only sporadic cases were used for analyses. Pathogenicity of variants was
determined using pathogenic status in AD&FTD and PD mutation databases [36].
2.6 Association analyses
Quality control filtering was performed on the VCF using VCFtools. Individuals were removed if
genotyping rate <97%, followed by markers with call rate <98%. Markers with significant deviation
(P<0.001) from the Hardy-Weinberg equilibrium in control individuals were removed. After removing
samples and markers failing quality control, 290 individuals remained with 76,640 non-singleton
variants in coding regions. The average genotyping rate was 99.9%.
Plink files were imported to PLINK-SEQ [37] (https://atgu.mgh.harvard.edu/plinkseq/). Single-variant
association was performed on samples using a logistic regression test correcting for the covariates
sex, age at death and APOE ε4 allele count. 
Gene-based association for genes of interest was calculated in R using a SKAT-O [38] burden test.
The C-alpha test was used for exome-wide analysis and the SKAT-O test was used for selected
genes.
2.7 Polygenic risk scoring
PRS were generated for BDR samples using PRSice [39]. The International Genomics of Alzheimer’s
Project (IGAP) summary data was used as the base dataset, collated from 17,008 LOAD cases and
37,154 controls. A region of 500kb around the APOE locus was excluded from the analysis. The best-
fit model with the greatest predictive accuracy was computed using area under the curve (AUC) in
SPSS. Additional predictor variables included were the number of APOE ε4 and ε2 alleles, age, sex 
and genotypes for the GWAS SNPs.
3. Results
3.1 Overview of data
Exome-sequencing was performed on a total of 292 individuals. The final cohort consisted of 132
LOAD cases and 53 control samples after quality control filtering. A total of 157,217 non-singleton
variants were present in 290 individuals, with a minimum of 2 alleles observed per variant. Filtering to
retain only coding mutations resulted in 76,640 variants for exome-wide analysis.
3.2 Exome-wide analyses
Burden analysis using a C-alpha test highlighted some nominally significant gene associations with
AD, shown in Table 2. PILRA and PRSS45 are just below the Bonferroni-corrected threshold (P=2x10-
6) at P=3.4x10-5 and P=5.9x10-5, respectively. PILRA has previously been linked to AD through
ZCWPW1, which was highlighted by the GWAS meta-analysis [9]. Five variants in PILRA contribute to
the effect: intronic variants rs7792525, rs190071731 and rs148891131, synonymous mutation
rs2405442 and missense variant p.S279L (rs34266222). GWAS SNP rs1476679 is in weak LD with
rs2405442 (R2=0.50). This mutation is tolerated as predicted by SIFT and Polyphen2. The other genes
have not previously been linked to AD. PRSS45 contains 5 variants that drive this signal, of which 2
were highly associated with disease (Table 3), therefore it is possible that these SNPs are contributing
to the signal.
Exome-wide association analysis was performed on the non-singleton variants, correcting for age, sex
and APOE ε4 status of individuals. As expected, APOE SNP rs429358 showed the most significant
association prior to adjusting for covariates (P=7.2x10-9, OR=6.5 [3.2-13.1]). There were no significant
associations at the genome-wide threshold (P=5x10-8) or at the suggestive threshold (P=1x10-5) after
correction. However due to low sample numbers, we do not have the power to detect any association
at that level. Some tentative associations were observed and are shown in Table 3.
Several of the genes encompassing variants are involved in signaling pathways, including serine
proteases PRSS42 and PRSS45 and inositol triphosphate receptor ITPR3. SIFT and Polyphen2
predictions indicate that most mutations are benign or tolerated. However missense mutations
TMEM260 p.A245S/T (rs17776256) and AVPR1B p.K65N (rs35369693) were predicted to be probably
damaging by both software. Both variants are more frequent in control samples, signifying a protective
effect. MEP1B is a metalloprotease recently implicated in APP cleavage and has been implicated in
inflammation. The synonymous variant p.S537 (rs173032) has an odds ratio of 3.1 (1.6-5.9) and has a
significantly greater frequency in cases than controls, inferring an association with AD. Two missense
mutations in PRSS45 are associated with protection against AD, p.I190L (rs58830807) and P130Q
(rs58943210) however both are predicted to be benign. None of the genes aside from MEP1B have
been directly linked to dementia.
3.3 Polygenic risk scoring
A 500kb region around the APOE gene containing 227 variants was excluded from the analysis to
identify effects independent of APOE. The predictive accuracy of each tested model is given in Table
4, denoted by area under the curve (AUC), with 95% confidence intervals. The APOE ε4 allele alone 
has 71.8% accuracy in discriminating between cases and controls, however this is a poor fit model.
Other covariates ε2, age, sex and GWAS greatly increase the predictive power 83.0%. In total 3,268 
variants were utilised to score risk of developing AD using the best fit model, which had a predictive
accuracy of 83.8% when combined with all covariates as predictors. The addition of PRS only
increased this accuracy by 0.8%, which is similar to improvements seen in other studies. There is
overlap between scores for both groups, however on average scores were higher for cases. Mean
scores for AD cases were 3.6x10-4 compared to 2.7x10-4 for control samples.
3.4 Screening for familial mutations
Samples were screened for mutations in fEOAD genes to remove any non-sporadic cases. A total of 6
coding variants were found in APP (1), PSEN1 (1) and PSEN2 (4), shown in Table 5. All individuals
were heterozygous for the variants listed and mutations were synonymous except two identified as
missense. PSEN1 p.E318G (rs17125721) was classified as a risk modifier but not pathogenic, found
in 5 cases and 1 control sample. PSEN2 p.S130L (rs63750197) was previously identified as possibly
damaging in silico with unclear pathogenicity, present in 1 case and 1 control. Both SNPs were
predicted to be deleterious depending on the transcript. However, no causative or fully penetrant
pathogenic mutations were observed in these genes, confirming that these samples are representative
of sporadic AD.
Other known neurologic genes were also screened for potential pathogenic mutations to identify
genetic overlap between sporadic LOAD and other neurodegenerative diseases (Table 6). Mutations
in Parkinson’s genes LRRK2, PARK2 and PINK1 appear to have some possibly damaging
consequences on the proteins. PARK2 p.R275W (rs34424986) is very rare and present in 1 AD case
and 1 control sample with mild cerebral amyloid angiopathy and presence of an unspecified dementia.
SIFT/Polyphen2 predictions both indicate a potentially deleterious effect of this mutation. Variant
p.P246L (rs149953814) was also found in 1 case and control, both also presenting with mild non-
amyloid small vessel disease. Samples were heterozygous for both variants.
Previously uncharacterised mutations were found in CHMP2B and LRRK2. The frameshift variant in
CHMP2B was seen in a healthy control and an individual with AD. The LRRK2 mutation was
heterozygous in a sample of each phenotype and results in a p.L1271P change. PRNP p.M129V
(rs1799990) has previously been implicated as a risk factor for prion disease, here however it is
observed in an equal number of case and controls, suggesting no effect in AD.
3.5 Association analyses of known neurologic genes
Following on from this, genes were selected based on whether they had been linked to AD or other
neurological diseases. Direct functionality was inferred from data filtered for coding variants only. A
total of 76,640 variants were annotated as coding mutations, with 219 variants in 35 of the selected
genes. Association and burden analyses were performed as before on the subset of variants. No
coding variants were identified in AD genes HLA-DRB1, HLA-DRB5 and MEF2C or the other
neurologic genes MAPT and TARDBP.
We performed single variant association on all 219 variants in the selected genes. No variants
reached genome-wide or suggestive levels of significance as identified by a logistic regression test
with correction for covariates. The most significant associations (P<0.05) are listed in Table 7. Results
for all 219 variants are shown in supplementary Table S2.
A large proportion of the highly associated variants are synonymous mutations. Four ABCA7 variants
are present, with 2 suggesting increased risk (OR>1) and 2 showing a protective effect (OR<1).
ABCA7 rs3752234 and rs3752237 are both synonymous mutations that increase risk more than 2-
fold. SLC24A4 synonymous SNP (rs7144273) also showed strong effects in the risk direction
(OR=1.63, P=0.018).
The majority of variants appear to be exhibiting a protective effect as indicated by the odds ratios, as
they were observed more frequently in control samples. LRRK2 p.M1646T (rs35303786) missense is
predicted as benign, however it is found in a greater frequency in control samples (OR=0.14,
P=0.018). We calculated gene-based burden using a SKAT-O test to provide greater statistical power
than that of a single-marker test (Table 8). Both sets of familial genes did not appear to exhibit any
burden on LOAD. Burden analysis revealed two significant associations; APOE and CLU were the
only genes to reach significance (P<0.05). However, they would not pass Bonferroni correction
(P=0.0014). Five variants in CLU contributed to the effect seen, which was corrected for age, sex and
APOE ε4 status. Two of these variants were significant, synonymous variant rs9331939 and 
rs149859119 (p.S16R), therefore they could be driving the signal in this gene.
4. Discussion
In this study, we initially investigated genetic association with LOAD using an exome-wide approach.
Although the analyses did not find any significant associations when corrected for multiple testing, the
sample size only provides enough power to detect common variant (MAF>5%) associations with an
effect size above 2.2 with 80% certainty. Nonetheless, single variant analysis highlighted some
interesting tentative associations which may merit further exploration.
Burden analysis revealed a tentative association with PILRA, an inhibitory immunoglobulin receptor
involved in regulating signal transduction in the immune system. This gene has previously been linked
to AD via its interaction with paired activation receptor PILRB and GWAS hit ZCWPW1. It is expressed
on myeloid cells and works with PILRB, which also associates with DAP12 and TREM2 [40]. PILRA
SNP rs2405442 is in weak LD (r2=0.5) with GWAS SNP rs1476679, suggesting this signal is likely to
be independent of the GWAS association. ZCWPW1 locus SNP rs1476679 was nominally associated
with reduced PILRA levels [41]. This suggests a potential role for the gene in AD, highlighting the need
for further investigation.
Many of the remaining genes on the burden list are enzymes with serine/threonine activity or serine
proteases, such as PRSS45, BCR, KLK2 and THNSL2. Efficient breakdown of proteins is important as
impairments in this can lead to the buildup of misfolded proteins. Dysfunction of the amyloid protein
degradation pathway has been implicated in AD. None of these genes have been previously linked to
AD. However in combination, enzymes regulating protein function and breakdown could play a greater
role in disease and this too warrants further exploration.
Multiple PRSS45 variants were observed, with two missense mutations found to be associated with
AD, exerting a protective effect. However, functional predictions indicate that both polymorphisms are
benign. This gene encodes a serine protease, part of a group of enzymes that cleave peptide bonds.
PRSS45 SNPs were also highly associated when tested in burden. Missense variants TMEM260
p.A245S and AVPR1B p.K65N were both predicted to be damaging to the protein in silico and found
more frequently in control samples. The function of TMEM260 is not clearly understood, whereas
AVPR1B is a vasopressin receptor located in the anterior pituitary gland that stimulates ACTH release.
AVPR1B SNP rs35369693 has been linked to mood disorders and found more frequently in affected
females [42]. The mutation in MEP1B, known as meprin β is synonymous; recent proteomic studies 
have found that these metalloproteases can cleave APP, affecting Aβ levels [43,44]. While these 
associations are tentative, examination of other larger datasets could be worthwhile.
PRS generated for individuals showed that, on average, scores were significantly higher in LOAD
cases than controls, despite an overlap amongst the cohort. Using sex, age at death, APOE ε4 and ε2 
allele counts and GWAS SNP genotypes as variables for prediction, the model was able to distinguish
cases and control with 83.8% accuracy. A total of 3,268 variants were used to predict disease risk.
The presence of controls with high risk scores suggests that these individuals may have gone on to
develop AD had they lived longer. The utility of PRS has already been demonstrated in AD, with
individuals’ genetic risk profiles able to predict disease susceptibility with more than 80% accuracy
[45]. However, there were controls with high PRS and no phenotypic changes indicative of dementia
and also cases with low PRS. Although PRS can identify more of the genetic component of AD, this
shows that there is still unexplained missing heritability.
Mutations in familial AD genes, APP, PSEN1 and PSEN2 are rare but highly penetrant. Screening of
these genes revealed no pathogenic variants and samples harbouring mutations were heterozygotes,
confirming there were no familial EOAD cases amongst the BDR LOAD classified cases. Other
neurologic familial genes were also screened for pathogenic mutations linked to related dementias. No
known causative mutations were identified, however PARK2 p.R275W was predicted to be deleterious
and has unknown pathogenicity in the PD mutation database. It produces an unusual distribution of
parkin with large cytoplasmic and nuclear inclusions [46]. The variant was present in one case and
control sample, however, which suggests that it is likely benign and not pathogenic in nature.
Previously uncharacterised mutations were identified in CHMP2B and LRRK2, with a frameshift
variant in CHMP2B and a missense variant in LRRK2. The frameshift variant was only seen in one
control sample, suggesting that it could be a sequencing artifact. LRRK2 p.L1271P is present in a
case and control sample so does not appear to segregate with disease. PRNP p.M129V has been
highlighted as a risk factor for prion disease but appears not to be having any effect in AD.
TREM2 mutation p.R47H was observed in 3 AD case samples which were heterozygotes. This variant
can increase risk of developing AD by 2-3 fold [12,47]. DNA was available for these 3 samples and
Sanger sequencing confirmed the presence of the variant in these subjects. No control samples
harboured this variant. However, given the documented frequency of R47H (MAF=0.002) this cohort
appears to have a greater MAF of 0.008. This 4-fold greater frequency will be verified as the BDR
sample set increases in size.
Single variant association of all neurologic gene variants revealed several synonymous mutations to
be nominally associated with AD at P<0.05. The majority of variants exerted effects in the protective
direction with greater frequency in controls than case samples. Four ABCA7 variants were significantly
associated at P<0.05 with 2 increasing risk and 2 being protective. Synonymous variants rs3752234
and rs3752237 increased AD risk more than 2-fold, which is contradictory to previous findings [48,49],
where the effects were protective. Conversely, rs4147915 and missense mutation rs3764645 p.E188G
are protective. ABCA7 p.E188G is predicted as tolerated and previously shown to have no effect on
disease risk [48]. These findings need to be validated as the sample size increases.
Missense variant LRRK2 p.M1646T was associated with protection against AD, but the amino acid
substitution is predicted to be tolerated. However the mutation is known to increase risk of developing
PD [50]. LRRK2 mutations have previously been linked to AD with PD risk variant p.R1628P found in
greater frequencies in AD cases than controls [51]. The variant increased apoptosis and cell death in
transfected human cell lines. Therefore, it is likely that genetic pleiotropy possibly occurs across
several neurodegenerative diseases. LRRK2 is involved in autophagy and recycling proteins in the
retrograde trafficking pathway. Mutations in this protein are associated with dendrite shortening in
neurons, a possible cause of motor symptoms in PD [46]. With some shared clinical features,
mutations in LRRK2 could also affect the autophagy process in AD.
Gene-based burden analysis in SKAT-O allowed adjustment to correct for the effect of age, sex and
number of APOE ε4 alleles. Both AD and other neurologic familial genes did not exhibit any burden on 
LOAD. APOE and CLU were significant to P<0.05 but did not pass Bonferroni correction. Only SNP
p.S16R in CLU was significantly associated in single variant testing, indicating that this is driving the
signal.
5. Conclusion
Although other familial neurologic genes did not show any burden on LOAD, an individual missense
variant in LRRK2 was tentatively associated; preliminary exploration of the data has indicated that
genetic pleiotropy is likely to play a role in diseases with overlapping features. LRRK2 is involved in
PD, yet few studies have investigated its role in other dementias.
Exome-wide analysis has revealed a significant burden of PILRA variants on AD. Previous studies
have identified a possible link with AD via GWAS hit ZCWPW1 and paired receptor PILRB which
associates with DAP12 and TREM2. PILRA and PILRB function may be co-regulated and therefore
further investigation should involve looking at both genes in AD.
Limitations in power have made it difficult to find many significant associations, but with on-going data
collection, the sample size will increase to address this issue. However, using an exome sequencing
approach it has been possible to detect rare variants with greater effect sizes, which previous GWAS
did not permit.
Supplementary Information
Supplementary Table S1. Summary data of all case and control samples used for analysis.
Supplementary Table S2. Variants found in AD-related genes in 129 LOAD cases and 53 controls.
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